RECQL4 and melanoma: Interestingly, high baseline RECQL4 expression was also predictive of shorter PFS (p = 2.07e‐02) and OS (p = 2.79e‐04) in melanoma patients receiving immune checkpoint‐targeted therapy (Figure 5E,F).